Real-World Implementation of Video-Observed Therapy for Tuberculosis Disease and Infection Monitoring Across U.S. Health Departments: A Systematic Review of Observational Evidence and Sociodemographic Subgroup Outcomes
This systematic review of U.S. observational and randomized studies concludes that video-observed therapy (VDOT) is at least as effective as in-person directly observed therapy for tuberculosis treatment adherence and completion, though evidence regarding sociodemographic subgroup outcomes remains limited and heterogeneous.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For decades, the standard way to ensure a patient takes their tuberculosis medication has been a health worker standing right beside them, watching them swallow each pill. This method, known as directly observed therapy, or DOT, was designed to prevent the disease from returning or becoming resistant to drugs by guaranteeing that every dose is taken. However, this approach requires significant time and resources, often demanding that patients travel to a clinic or that staff drive to a patient's home. As technology advanced, health officials began asking if a video call could replace the in-person visit. This newer method, called video-observed therapy, or VDOT, allows patients to record themselves taking their medicine or to connect live with a nurse via a smartphone or computer. The question became whether this digital alternative could work just as well as the traditional method, especially across the diverse landscapes of the United States, where patient needs and resources vary widely.
A recent systematic review set out to answer this question by gathering and analyzing ten real-world studies conducted within U.S. health departments. The researchers looked at data from both active tuberculosis disease and the treatment of latent tuberculosis infection, which is a dormant form of the bacteria that can be prevented from becoming active. They compared programs using video monitoring against those using the traditional in-person approach. The review found that in every single study examined, the video method performed at least as well as the in-person method for helping patients finish their treatment. In fact, no study found that the traditional in-person method was superior to the video method. When the researchers combined the data from the most comparable studies, they found a small but statistically significant advantage for the video approach in helping patients complete their full course of treatment for active disease. The improvement was measured at just over two percentage points, a modest gain that suggests video therapy is a reliable alternative, though not necessarily a miracle cure that drastically changes completion rates on its own.
The evidence for latent tuberculosis infection, the preventive treatment, told a slightly more complex story. When the researchers looked at studies involving this specific group, the video method appeared to show a much larger improvement in treatment completion, with a difference of nearly fifteen percentage points in one analysis. However, the researchers noted that this result was highly inconsistent across the different studies and was driven largely by one older comparison rather than a consistent pattern. Because of this inconsistency, the review suggests that this larger number should be viewed as a promising hint for future research rather than a confirmed fact. What was clear across all the studies, however, was that the video method consistently cost less. Whether looking at the cost per session for a patient or the overall expense for a health program, the video approach saved money, with some estimates showing savings of over a thousand dollars per patient for a standard six-month treatment course.
One of the most critical findings of the review concerned how we measure success. In many of the observational studies, the video method showed huge jumps in the number of doses that were actually seen or verified, with some studies reporting improvements of twenty to thirty percentage points in observation rates. It is easy to assume that seeing more doses means more patients will finish their treatment, but the data showed this was not necessarily true. The small, steady improvement in actual treatment completion did not match the large spikes in observation rates. This distinction is vital for health officials planning these programs; while video therapy makes it much easier to watch patients take their pills, it does not automatically translate into a massive surge in the number of people who finish their entire regimen. The video method is effective, but it is not a magic switch that solves all the complex reasons why people might stop taking their medication.
The review also highlighted a significant gap in our understanding of who benefits most from this technology. Out of the ten studies analyzed, only one looked closely at how different groups of people responded to video therapy. That single study found that patients born in the United States or Mexico had lower adherence to the video method compared to those born in other countries. While this is an important signal, the researchers could not explain why this difference existed. It remains unclear if the cause is related to digital literacy, work schedules, housing stability, or technical barriers. Because so few studies have examined these demographic differences, health departments cannot yet be sure that the video method works equally well for everyone. The review concludes that while video-observed therapy is a proven, cost-effective alternative to in-person visits, future work must focus on understanding these subgroup differences and ensuring that the technology serves all patients fairly, rather than assuming that a higher rate of watching doses leads to a proportionally higher rate of finishing treatment.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.